The SEARCH study aims to address if an HIV test and treat strategy can ‘shut down’ new HIV infections; to show how it can best be done and its cost and cost savings. In Phase I, our hypothesis is that ART initiation at any CD4 count with streamlined delivery compared to current country guidelines will reduce cumulative HIV incidence and protect and improve health, economic and education outcomes in communities with annual HIV testing campaigns. In Phase II, our hypothesis is targeted PrEP, targeted HIV testing, and targeted care interventions on top of universal treatment and streamlined care, will reduce cumulative 3-year HIV incidence in men and women >15 years and improve other health and economic outcomes.
We will also be looking at the health-related and economic/education outcomes including: 1) mortality (overall, maternal, and infant mortality), 2) mother-to-child HIV transmission, 3) AIDS (WHO stage 4), 4) tuberculosis, 5) HIV drug resistance, 6) adult and child employment levels, 7) asset holdings, 8) school attendance levels, 9) programmatic costs, 10) health gains expressed in averted Disability Adjusted Life Years (DALY), and 11) cost effectiveness (e.g. cost per infection averted and per DALY averted).
You can learn more about the SEARCH study at Clinicaltrials.gov.